Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

A 64-year-old male was treated continuously with rifampin, isoniazid and streptomycin for pulmonary atypical mycobacteriosis, Mycobacterium kansasii. Five weeks after beginning the treatment, the patient suddenly developed acute renal failure. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis with moderate interstitial changes. Serum antirifampin antibody was detected, and the cessation of rifampin treatment was followed by a rapid spontaneous recovery of the patient's renal function. This is, to our knowledge, the first case of rapidly progressive crescentic glomerulonephritis associated with rifampin treatment where circulating antirifampin antibody is demonstrated and the renal function spontaneously improved after discontinuing rifampin treatment.

Original languageEnglish
Pages (from-to)319-322
Number of pages4
JournalNephron
Volume78
Issue number3
DOIs
Publication statusPublished - Mar 19 1998

Fingerprint

Rifampin
Glomerulonephritis
Lung
Kidney
Mycobacterium kansasii
Nontuberculous Mycobacteria
Withholding Treatment
Antibodies
Isoniazid
Streptomycin
Therapeutics
Acute Kidney Injury
Biopsy
Serum

All Science Journal Classification (ASJC) codes

  • Physiology
  • Nephrology
  • Urology
  • Physiology (medical)

Cite this

Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis. / Ogata, Hisanobu.

In: Nephron, Vol. 78, No. 3, 19.03.1998, p. 319-322.

Research output: Contribution to journalArticle

@article{7a9f296577c94953b5d9e60773414d40,
title = "Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis",
abstract = "A 64-year-old male was treated continuously with rifampin, isoniazid and streptomycin for pulmonary atypical mycobacteriosis, Mycobacterium kansasii. Five weeks after beginning the treatment, the patient suddenly developed acute renal failure. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis with moderate interstitial changes. Serum antirifampin antibody was detected, and the cessation of rifampin treatment was followed by a rapid spontaneous recovery of the patient's renal function. This is, to our knowledge, the first case of rapidly progressive crescentic glomerulonephritis associated with rifampin treatment where circulating antirifampin antibody is demonstrated and the renal function spontaneously improved after discontinuing rifampin treatment.",
author = "Hisanobu Ogata",
year = "1998",
month = "3",
day = "19",
doi = "10.1159/000044942",
language = "English",
volume = "78",
pages = "319--322",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Crescentic glomerulonephritis due to rifampin treatment in a patient with pulmonary atypical mycobacteriosis

AU - Ogata, Hisanobu

PY - 1998/3/19

Y1 - 1998/3/19

N2 - A 64-year-old male was treated continuously with rifampin, isoniazid and streptomycin for pulmonary atypical mycobacteriosis, Mycobacterium kansasii. Five weeks after beginning the treatment, the patient suddenly developed acute renal failure. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis with moderate interstitial changes. Serum antirifampin antibody was detected, and the cessation of rifampin treatment was followed by a rapid spontaneous recovery of the patient's renal function. This is, to our knowledge, the first case of rapidly progressive crescentic glomerulonephritis associated with rifampin treatment where circulating antirifampin antibody is demonstrated and the renal function spontaneously improved after discontinuing rifampin treatment.

AB - A 64-year-old male was treated continuously with rifampin, isoniazid and streptomycin for pulmonary atypical mycobacteriosis, Mycobacterium kansasii. Five weeks after beginning the treatment, the patient suddenly developed acute renal failure. A renal biopsy showed crescentic lesions characteristic of rapidly progressive glomerulonephritis with moderate interstitial changes. Serum antirifampin antibody was detected, and the cessation of rifampin treatment was followed by a rapid spontaneous recovery of the patient's renal function. This is, to our knowledge, the first case of rapidly progressive crescentic glomerulonephritis associated with rifampin treatment where circulating antirifampin antibody is demonstrated and the renal function spontaneously improved after discontinuing rifampin treatment.

UR - http://www.scopus.com/inward/record.url?scp=0031952099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031952099&partnerID=8YFLogxK

U2 - 10.1159/000044942

DO - 10.1159/000044942

M3 - Article

VL - 78

SP - 319

EP - 322

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 3

ER -